Sandoz Says Amgen Biosimilar Claims Conflict With ACA
Sandoz Inc. is fighting Amgen Inc.'s claims that biosimilars makers must share information with rivals and refrain from marketing copycat products for six months after winning approval, telling a California federal...To view the full article, register now.
Already a subscriber? Click here to view full article